mTOR in growth and protection of hypertrophying myocardium

Cardiovascular and Hematological Agents in Medicinal Chemistry

Volumn 7, Issue 1, 2009, Pages 52-63

  Balasubramanian, Sundaravadivel ^a   Johnston, Rebecca K ^a   Moschella, Phillip C ^a   Mani, Santhosh K ^a   Tuxworth Jr , William J ^a   Kuppuswamy, Dhandapani ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

Akt; Cardiac hypertrophy; mTOR; PI3K; PKC; Rapamycin; S6K; Ubiquitination

Indexed keywords

ACTIN; ADRENERGIC RECEPTOR; GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTEGRIN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PROTEIN KINASE B; PROTEIN KINASE C ALPHA; RAPAMYCIN; TACROLIMUS; UBIQUITIN; UNCLASSIFIED DRUG; PROTEIN KINASE;

CELL SIZE; CELL SURVIVAL; CYTOSKELETON; DRUG MECHANISM; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE FUNCTION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE OVERLOAD; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REPERFUSION INJURY; REVIEW; UBIQUITINATION; ADAPTATION; CARDIOMEGALY; CELL PROLIFERATION; CYTOLOGY; HEART MUSCLE CELL; PHYSIOLOGY;

ADAPTATION, PHYSIOLOGICAL; CARDIOMEGALY; CELL PROLIFERATION; CELL SURVIVAL; HUMANS; MYOCYTES, CARDIAC; PROTEIN KINASES; SIROLIMUS;

EID: 64149090178     PISSN: 18715257     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152509787047603     Document Type: Review

References (119)

1. Cooper, G., 4th. Basic determinants of myocardial hypertrophy: a review of molecular mechanisms. Annu. Rev. Med., 1997, 48, 13.
2. Wullschleger, S.; Loewith, R.; Hall, M.N. TOR signaling in growth and metabolism. Cell, 2006, 124, 471.
3. Sarbassov, D.D.; Ali, S.M.; Sabatini, D.M. Growing roles for the mTOR pathway. Curr. Opin. Cell Biol., 2005, 17, 596.
4. Chiang, G.G.; Abraham, R.T. Targeting the mTOR signaling network in cancer. Trends Mol. Med, 2007, 13, 433.
5. Park, I.H.; Erbay, E.; Nuzzi, P.; Chen, J. Skeletal myocyte hypertrophy requires mTOR kinase activity and S6K1. Exp. Cell Res., 2005, 309, 211.
6. Jacinto, E.; Loewith, R.; Schmidt, A.; Lin, S.; Ruegg, M.A.; Hall, A.; Hall, M.N. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol., 2004, 6, 1122.
7. Sarbassov, D.D.; Ali, S.M.; Kim, D.H.; Guertin, D.A.; Latek, R.R.; Erdjument-Bromage, H.; Tempst, P.; Sabatini, D.M. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol., 2004, 14, 1296.
8. Sarbassov, D.D.; Guertin, D.A.; Ali, S.M.; Sabatini, D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science, 2005, 307, 1098.
9. Guertin, D.A.; Stevens, D.M.; Thoreen, C.C.; Burds, A.A.; Kalaany, N.Y.; Moffat, J.; Brown, M.; Fitzgerald, K.J.; Sabatini, D.M. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev. Cell, 2006, 11, 859.
10. Laser, M.; Kasi, V.S.; Hamawaki, M.; Cooper, G., 4th.; Kerr, C.M.; Kuppuswamy, D. Differential activation of p70 and p85 S6 kinase isoforms during cardiac hypertrophy in the adult mammal. J. Biol. Chem., 1998, 273, 24610.
11. Iijima, Y.; Laser, M.; Shiraishi, H.; Willey, C.D.; Sundaravadivel, B.; Xu, L.; McDermott, P.J.; Kuppuswamy, D. c-Raf/MEK/ERK pathway controls protein kinase C-mediated p70S6K activation in adult cardiac muscle cells. J. Biol. Chem., 2002, 277, 23065.
12. Balasubramanian, S.; Kuppuswamy, D. RGD-containing peptides activate S6K1 through beta3 integrin in adult cardiac muscle cells. J. Biol. Chem., 2003, 278, 42214.
13. Naga Prasad, S.V.; Perrino, C.; Rockman, H.A. Role of phosphoinositide 3-kinase in cardiac function and heart failure. Trends Cardiovasc. Med., 2003, 13, 206.
14. Shioi, T.; McMullen, J.R.; Tarnavski, O.; Converso, K.; Sherwood, M.C.; Manning, W.J.; Izumo, S. Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation, 2003, 107, 1664.
15. Veverka, V.; Crabbe, T.; Bird, I.; Lennie, G.; Muskett, F.W.; Taylor, R.J.; Carr, M.D. Structural characterization of the interaction of mTOR with phosphatidic acid and a novel class of inhibitor: compelling evidence for a central role of the FRB domain in small molecule-mediated regulation of mTOR. Oncogene, 2008, 27, 585.
16. Leone, M.; Crowell, K.J.; Chen, J.; Jung, D.; Chiang, G.G.; Sareth, S.; Abraham, R.T.; Pellecchia, M. The FRB domain of mTOR: NMR solution structure and inhibitor design. Biochemistry, 2006, 45, 10294.
17. Loewith, R.; Jacinto, E.; Wullschleger, S.; Lorberg, A.; Crespo, J.L.; Bonenfant, D.; Oppliger, W.; Jenoe, P.; Hall, M.N. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol. Cell, 2002, 10, 457.
18. Woo, S.Y.; Kim, D.H.; Jun, C.B.; Kim, Y.M.; Haar, E.V.; Lee, S.I.; Hegg, J.W.; Bandhakavi, S.; Griffin, T.J.; Kim, D.H. PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling. J. Biol. Chem., 2007, 282, 25604.
19. Saucedo, L.J.; Gao, X.; Chiarelli, D.A.; Li, L.; Pan, D.; Edgar, B.A. Rheb promotes cell growth as a component of the insulin/TOR signalling network. Nat. Cell Biol., 2003, 5, 566.
20. Potter, C.J.; Huang, H.; Xu, T. Drosophila Tsc1 functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size. Cell, 2001, 105, 357.
21. Tapon, N.; Ito, N.; Dickson, B.J.; Treisman, J.E.; Hariharan, I.K. The Drosophila tuberous sclerosis complex gene homologs restrict cell growth and cell proliferation. Cell, 2001, 105, 345.
22. Gao, X.; Pan, D. TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth. Genes Dev., 2001, 15, 1383.
23. Inoki, K.; Zhu, T.; Guan, K.L. TSC2 mediates cellular energy response to control cell growth and survival. Cell, 2003, 115, 577.
24. Sadoshima, J.; Izumo, S. Rapamycin selectively inhibits angiotensin II-induced increase in protein synthesis in cardiac myocytes in vitro. Potential role of 70-kD S6 kinase in angiotensin II-induced cardiac hypertrophy. Circ. Res., 1995, 77, 1040.
25. Simm, A.; Schluter, K.; Diez, C.; Piper, H.M.; Hoppe, J. Activation of p70(S6) kinase by beta-adrenoceptor agonists on adult cardiomyocytes. J. Mol. Cell. Cardiol., 1998, 30, 2059.
26. Wang, L.; Gout, I.; Proud, C.G. Cross-talk between the ERK and p70 S6 kinase (S6K) signaling pathways. MEK-dependent activation of S6K2 in cardiomyocytes. J. Biol. Chem., 2001, 276, 32670.
27. Shioi, T.; McMullen, J.R.; Kang, P.M.; Douglas, P.S.; Obata, T.; Franke, T.F.; Cantley, L.C.; Izumo, S. Akt/protein kinase B promotes organ growth in transgenic mice. Mol. Cell. Biol., 2002, 22, 2799.
28. McMullen, J.R.; Sherwood, M.C.; Tarnavski, O.; Zhang, L.; Dorfman, A.L.; Shioi, T.; Izumo, S. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation, 2004, 109, 3050.
29. Proud, C.G. Ras, PI3-kinase and mTOR signaling in cardiac hypertrophy. Cardiovasc. Res., 2004, 63, 403.
30. Moschella, P.C.; Rao, V.U.; McDermott, P.J.; Kuppuswamy, D. Regulation of mTOR and S6K1 activation by the nPKC isoforms, PKCepsilon and PKCdelta, in adult cardiac muscle cells. J. Mol. Cell. Cardiol., 2007, 43, 754.
31. Tuxworth, W.J., Jr.; Shiraishi, H.; Moschella, P.C.; Yamane, K.; McDermott, P.J.; Kuppuswamy, D. Translational activation of 5′-TOP mRNA in pressure overload myocardium. Basic Res. Cardiol., 2008, 103, 41.
32. Naga Prasad, S.V.; Esposito, G.; Mao, L.; Koch, W.J.; Rockman, H.A. Gbetagamma-dependent phosphoinositide 3-kinase activation in hearts with in vivo pressure overload hypertrophy. J. Biol. Chem., 2000, 275, 4693.
33. Yan, Y.; Backer, J.M. Regulation of class III (Vps34) PI3Ks. Biochem. Soc. Trans., 2007, 35, 239.
34. Hresko, R.C.; Mueckler, M. mTOR.RICTOR is the Ser473 kinase for Akt/ protein kinase B in 3T3-L1 adipocytes. J. Biol. Chem., 2005, 280, 40406.
35. Corradetti, M.N.; Guan, K.L. Upstream of the mammalian target of rapamycin: do all roads pass through mTOR? Oncogene, 2006, 25, 6347.
36. Mao, K.; Kobayashi, S.; Jaffer, Z.M.; Huang, Y.; Volden, P.; Chernoff, J.; Liang, Q. Regulation of Akt/PKB activity by P21-activated kinase in cardiomyocytes. J. Mol. Cell. Cardiol., 2007.
37. McDonald, P.C.; Oloumi, A.; Mills, J.; Dobreva, I.; Maidan, M.; Gray, V.; Wederell, E.D.; Bally, M.B.; Foster, L.J.; Dedhar, S. Rictor and integrin-linked kinase interact and regulate Akt phosphorylation and cancer cell survival. Cancer Res., 2008, 68, 1618.
38. Martelli, A.M.; Cocco, L.; Capitani, S.; Miscia, S.; Papa, S.; Manzoli, F.A. Nuclear phosphatidylinositol 3,4,5-trisphosphate, phosphatidylinositol 3-kinase, Akt, and PTen: emerging key regulators of anti-apoptotic signaling and carcinogenesis. Eur. J. Histochem., 2007, 51 (Suppl. 1), 125.
39. Shiraishi, I.; Melendez, J.; Ahn, Y.; Skavdahl, M.; Murphy, E.; Welch, S.; Schaefer, E.; Walsh, K.; Rosenzweig, A.; Torella, D.; Nurzynska, D.; Kajstura, J.; Leri, A.; Anversa, P.; Sussman, M.A. Nuclear targeting of Akt enhances kinase activity and survival of cardiomyocytes. Circ. Res., 2004, 94, 884.
40. Proud, C.G. Regulation of protein synthesis by insulin. Biochem. Soc. Trans., 2006, 34, 213.
41. Holz, M.K.; Ballif, B.A.; Gygi, S.P.; Blenis, J. mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell, 2005, 123, 569.
42. Raught, B.; Peiretti, F.; Gingras, A.C.; Livingstone, M.; Shahbazian, D.; Mayeur, G.L.; Polakiewicz, R.D.; Sonenberg, N.; Hershey, J.W. Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases. EMBO J., 2004, 23, 1761.
43. Peterson, R.T.; Desai, B.N.; Hardwick, J.S.; Schreiber, S.L. Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycinassociated protein. Proc. Natl. Acad. Sci. USA, 1999, 96, 4438.
44. Wang, X.; Li, W.; Williams, M.; Terada, N.; Alessi, D.R.; Proud, C.G. Regulation of elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase. EMBO J., 2001, 20, 4370.
45. Senbonmatsu, T.; Ichihara, S.; Price, E., Jr.; Gaffney, F.A.; Inagami, T. Evidence for angiotensin II type 2 receptor-mediated cardiac myocyte enlargement during in vivo pressure overload. J. Clin. Invest., 2000, 106, R25.
46. Tuxworth, W.J., Jr.; Wada, H.; Ishibashi, Y.; McDermott, P.J. Role of load in regulating eIF-4F complex formation in adult feline cardiocytes. Am. J. Physiol., 1999, 277, H1273.
47. Shima, H.; Pende, M.; Chen, Y.; Fumagalli, S.; Thomas, G.; Kozma, S.C. Disruption of the p70(s6k)/p85(s6k) gene reveals a small mouse phenotype and a new functional S6 kinase. EMBO J., 1998, 17, 6649.
48. Pende, M. mTOR, Akt, S6 kinases and the control of skeletal muscle growth. Bull. Cancer, 2006, 93, E39.
49. McMullen, J.R.; Shioi, T.; Zhang, L.; Tarnavski, O.; Sherwood, M.C.; Dorfman, A.L.; Longnus, S.; Pende, M.; Martin, K.A.; Blenis, J.; Thomas, G.; Izumo, S. Deletion of ribosomal S6 kinases does not attenuate pathological, physiological, or insulin-like growth factor 1 receptor-phosphoinositide 3-kinase-induced cardiac hypertrophy. Mol. Cell. Biol., 2004, 24, 6231.
50. Boluyt, M.O.; Li, Z.B.; Loyd, A.M.; Scalia, A.F.; Cirrincione, G.M.; Jackson, R.R. The mTOR/p70S6K signal transduction pathway plays a role in cardiac hypertrophy and influences expression of myosin heavy chain genes in vivo. Cardiovasc. Drugs Ther., 2004, 18, 257.
51. Lee, C.H.; Inoki, K.; Guan, K.L. mTOR pathway as a target in tissue hypertrophy. Annu. Rev. Pharmacol. Toxicol., 2007, 47, 443.
52. Richardson, C.J.; Broenstrup, M.; Fingar, D.C.; Julich, K.; Ballif, B.A.; Gygi, S.; Blenis, J. SKAR is a specific target of S6 kinase 1 in cell growth control. Curr. Biol., 2004, 14, 1540.
53. Ma, X.M.; Yoon, S.O.; Richardson, C.J.; Julich, K.; Blenis, J. SKAR links pre-mRNA splicing to mTOR/S6K1-mediated enhanced translation efficiency of spliced mRNAs. Cell, 2008, 133, 303.
54. Levine, B.; Klionsky, D.J. Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev. Cell, 2004, 6, 463.
55. Rajawat, Y.S.; Bossis, I. Autophagy in aging and in neurodegenerative disorders. Hormones (Athens), 2008, 7, 46.
56. Wu, H.; Yang, J.M.; Jin, S.; Zhang, H.; Hait, W.N. Elongation factor-2 kinase regulates autophagy in human glioblastoma cells. Cancer Res., 2006, 66, 3015.
57. Sabatini, D.M. mTOR and cancer: insights into a complex relationship. Nat. Rev. Cancer, 2006, 6, 729.
58. Dudek, H.; Datta, S.R.; Franke, T.F.; Birnbaum, M.J.; Yao, R.; Cooper, G.M.; Segal, R.A.; Kaplan, D.R.; Greenberg, M.E. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science, 1997, 275, 661.
59. Shiojima, I.; Walsh, K. Role of Akt signaling in vascular homeostasis and angiogenesis. Circ. Res., 2002, 90, 1243.
60. Stephens, L.; Anderson, K.; Stokoe, D.; Erdjument-Bromage, H.; Painter, G.F.; Holmes, A.B.; Gaffney, P.R.; Reese, C.B.; McCormick, F.; Tempst, P.; Coadwell, J.; Hawkins, P.T. Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphatedependent activation of protein kinase B. Science, 1998, 279, 710.
61. Yao, R.; Cooper, G.M. Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. Science, 1995, 267, 2003.
62. Fujio, Y.; Nguyen, T.; Wencker, D.; Kitsis, R.N.; Walsh, K. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation, 2000, 101, 660.
63. Matsui, T.; Tao, J.; del Monte, F.; Lee, K.H.; Li, L.; Picard, M.; Force, T.L.; Franke, T.F.; Hajjar, R.J.; Rosenzweig, A. Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation, 2001, 104, 330.
64. Condorelli, G.; Drusco, A.; Stassi, G.; Bellacosa, A.; Roncarati, R.; Iaccarino, G.; Russo, M.A.; Gu, Y.; Dalton, N.; Chung, C.; Latronico, M.V.; Napoli, C.; Sadoshima, J.; Croce, C.M.; Ross, J., Jr. Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc. Natl. Acad. Sci. U.S.A., 2002, 99, 12333.
65. DeBosch, B.; Treskov, I.; Lupu, T.S.; Weinheimer, C.; Kovacs, A.; Courtois, M.; Muslin, A.J. Akt1 is required for physiological cardiac growth. Circulation, 2006, 113, 2097.
66. Shiojima, I.; Walsh, K. Regulation of cardiac growth and coronary angiogenesis by the Akt/PKB signaling pathway. Genes Dev., 2006, 20, 3347.
67. Kemi, O.J.; Ceci, M.; Wisloff, U.; Grimaldi, S.; Gallo, P.; Smith, G.L.; Condorelli, G.; Ellingsen, O. Activation or inactivation of cardiac Akt/ mTOR signaling diverges physiological from pathological hypertrophy. J. Cell. Physiol., 2008, 214, 316.
68. Walsh, K. Akt signaling and growth of the heart. Circulation, 2006, 113, 2032.
69. Rota, M.; Boni, A.; Urbanek, K.; Padin-Iruegas, M.E.; Kajstura, T.J.; Fiore, G.; Kubo, H.; Sonnenblick, E.H.; Musso, E.; Houser, S.R.; Leri, A.; Sussman, M.A.; Anversa, P. Nuclear targeting of Akt enhances ventricular function and myocyte contractility. Circ. Res., 2005, 97, 1332.
70. Heineke, J.; Molkentin, J.D. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat. Rev. Mol. Cell Biol., 2006, 7, 589.
71. Pickart, C.M. Mechanisms underlying ubiquitination. Annu. Rev. Biochem., 2001, 70, 503.
72. Pickart, C.M.; Eddins, M.J. Ubiquitin: structures, functions, mechanisms. Biochim. Biophys. Acta, 2004, 1695, 55.
73. Herrmann, J.; Ciechanover, A.; Lerman, L.O.; Lerman, A. The ubiquitin-proteasome system in cardiovascular diseases-a hypothesis extended. Cardiovasc. Res., 2004, 61, 11.
74. Hedhli, N.; Pelat, M.; Depre, C. Protein turnover in cardiac cell growth and survival. Cardiovasc. Res., 2005, 68, 186.
75. Zolk, O.; Schenke, C.; Sarikas, A. The ubiquitin-proteasome system: Focus on the heart. Cardiovasc. Res., 2006, 70, 410.
76. Powell, S.R. The ubiquitin proteasome system in cardiac physiology and pathology. Am. J. Physiol. Heart Circ. Physiol., 2006, 291, H1.
77. Depre, C.; Wang, Q.; Yan, L.; Hedhli, N.; Peter, P.; Chen, L.; Hong, C.; Hittinger, L.; Ghaleh, B.; Sadoshima, J.; Vatner, D.E.; Vatner, S.F.; Madura, K. Activation of the cardiac proteasome during pressure overload promotes ventricular hypertrophy. Circulation, 2006, 114, 1821.
78. Meiners, S.; Dreger, H.; Fechner, M.; Bieler, S.; Rother, W.; Gunther, C.; Baumann, G.; Stangl, V.; Stangl, K. Suppression of cardiomyocyte hypertrophy by inhibition of the ubiquitin-proteasome system. Hypertension, 2008, 51, 302.
79. Luo, J.; McMullen, J.R.; Sobkiw, C.L.; Zhang, L.; Dorfman, A.L.; Sherwood, M.C.; Logsdon, M.N.; Horner, J.W.; DePinho, R.A.; Izumo, S.; Cantley, L.C. Class IA phosphoinositide 3-kinase regulates heart size and physiological cardiac hypertrophy. Mol. Cell. Biol., 2005, 25, 9491.
80. Ha, T.; Li, Y.; Gao, X.; McMullen, J.R.; Shioi, T.; Izumo, S.; Kelley, J.L.; Zhao, A.; Haddad, G.E.; Williams, D.L.; Browder, I.W.; Kao, R.L.; Li, C. Attenuation of cardiac hypertrophy by inhibiting both mTOR and NFkappaB activation in vivo. Free Radic. Biol. Med., 2005, 39, 1570.
81. Chen, J.; Chen, Y.; Zhu, W.; Han, Y.; Han, B.; Xu, R.; Deng, L.; Cai, Y.; Cong, X.; Yang, Y.; Hu, S.; Chen, X. Specific LPA receptor subtype mediation of LPA-induced hypertrophy of cardiac myocytes and involvement of Akt and NFkappaB signal pathways. J. Cell. Biochem., 2007, 103, 1718.
82. Balasubramanian, S.; Mani, S.; Shiraishi, H.; Johnston, R.K.; Yamane, K.; Willey, C.D.; Cooper, G., 4th.; Tuxworth, W.J.; Kuppuswamy, D. Enhanced ubiquitination of cytoskeletal proteins in pressure overloaded myocardium is accompanied by changes in specific E3 ligases. J. Mol. Cell. Cardiol., 2006, 41, 669.
83. Weekes, J.; Morrison, K.; Mullen, A.; Wait, R.; Barton, P.; Dunn, M.J. Hyperubiquitination of proteins in dilated cardiomyopathy. Proteomics, 2003, 3, 208.
84. Kostin, S.; Pool, L.; Elsasser, A.; Hein, S.; Drexler, H.C.; Arnon, E.; Hayakawa, Y.; Zimmermann, R.; Bauer, E.; Klovekorn, W.P.; Schaper, J. Myocytes die by multiple mechanisms in failing human hearts. Circ. Res., 2003, 92, 715.
85. Tsukamoto, O.; Minamino, T.; Okada, K.; Shintani, Y.; Takashima, S.; Kato, H.; Liao, Y.; Okazaki, H.; Asai, M.; Hirata, A.; Fujita, M.; Asano, Y.; Yamazaki, S.; Asanuma, H.; Hori, M.; Kitakaze, M. Depression of proteasome activities during the progression of cardiac dysfunction in pressure-overloaded heart of mice. Biochem. Biophys. Res. Commun., 2006, 340, 1125.
86. Plas, D.R.; Thompson, C.B. Akt activation promotes degradation of tuberin and FOXO3a via the proteasome. J. Biol. Chem., 2003, 278, 12361.
87. Vogt, P.K.; Jiang, H.; Aoki, M. Triple layer control: phosphorylation, acetylation and ubiquitination of FOXO proteins. Cell Cycle, 2005, 4, 908.
88. Sacheck, J.M.; Ohtsuka, A.; McLary, S.C.; Goldberg, A.L. IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. Am. J. Physiol. Endocrinol. Metab., 2004, 287, E591.
89. Li, H.H.; Willis, M.S.; Lockyer, P.; Miller, N.; McDonough, H.; Glass, D.J.; Patterson, C. Atrogin-1 inhibits Akt-dependent cardiac hypertrophy in mice via ubiquitin-dependent coactivation of Forkhead proteins. J. Clin. Invest., 2007, 117, 3211.
90. Zhao, J.; Brault, J.J.; Schild, A.; Cao, P.; Sandri, M.; Schiaffino, S.; Lecker, S.H.; Goldberg, A.L. FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metab., 2007, 6, 472.
91. Mammucari, C.; Milan, G.; Romanello, V.; Masiero, E.; Rudolf, R.; Del Piccolo, P.; Burden, S.J.; Di Lisi, R.; Sandri, C.; Zhao, J.; Goldberg, A.L.; Schiaffino, S.; Sandri, M. FoxO3 controls autophagy in skeletal muscle in vivo. Cell Metab., 2007, 6, 458.
92. Li, Y.; Ha, T.; Gao, X.; Kelley, J.; Williams, D.L.; Browder, I.W.; Kao, R.L.; Li, C. NF-kappaB activation is required for the development of cardiac hypertrophy in vivo. Am. J. Physiol. Heart Circ. Physiol., 2004, 287, H1712.
93. Bernal-Mizrachi, L.; Lovly, C.M.; Ratner, L. The role of NF-{kappa}B-1 and NF-{kappa}B-2-mediated resistance to apoptosis in lymphomas. Proc. Natl. Acad. Sci. U.S.A., 2006, 103, 9220.
94. Hynes, R.O. Integrins: bidirectional, allosteric signaling machines. Cell, 2002, 110, 673.
95. Critchley, D.R. Cytoskeletal proteins talin and vinculin in integrin-mediated adhesion. Biochem. Soc. Trans., 2004, 32, 831.
96. Brancaccio, M.; Hirsch, E.; Notte, A.; Selvetella, G.; Lembo, G.; Tarone, G. Integrin signalling: the tug-of-war in heart hypertrophy. Cardiovasc. Res., 2006, 70, 422.
97. Sheppard, D. In vivo functions of integrins: lessons from null mutations in mice. Matrix Biol., 2000, 19, 203.
98. Nagai, T.; Laser, M.; Baicu, C.F.; Zile, M.R.; Cooper, G., 4th.; Kuppuswamy, D. Beta3-integrin-mediated focal adhesion complex formation: adult cardiocytes embedded in three-dimensional polymer matrices. Am. J. Cardiol., 1999, 83, 38H.
99. Willey, C.D.; Balasubramanian, S.; Rodriguez Rosas, M.C.; Ross, R.S.; Kuppuswamy, D. Focal complex formation in adult cardiomyocytes is accompanied by the activation of beta3 integrin and c-Src. J. Mol. Cell. Cardiol., 2003, 35, 671.
100. Shai, S.Y.; Harpf, A.E.; Babbitt, C.J.; Jordan, M.C.; Fishbein, M.C.; Chen, J.; Omura, M.; Leil, T.A.; Becker, K.D.; Jiang, M.; Smith, D.J.; Cherry, S.R.; Loftus, J.C.; Ross, R.S. Cardiac myocyte-specific excision of the beta1 integrin gene results in myocardial fibrosis and cardiac failure. Circ. Res., 2002, 90, 458.
101. Kuppuswamy, D.; Kerr, C.; Narishige, T.; Kasi, V.S.; Menick, D.R.; Cooper, G., 4th. Association of tyrosine-phosphorylated c-Src with the cytoskeleton of hypertrophying myocardium. J. Biol. Chem., 1997, 272, 4500.
102. Laser, M.; Willey, C.D.; Jiang, W.; Cooper, G., 4th.; Menick, D.R.; Zile, M.R.; Kuppuswamy, D. Integrin activation and focal complex formation in cardiac hypertrophy. J. Biol. Chem., 2000, 275, 35624.
103. Kuppuswamy, D. Importance of integrin signaling in myocyte growth and survival. Circ. Res., 2002, 90, 1240.
104. Berven, L.A.; Willard, F.S.; Crouch, M.F. Role of the p70(S6K) pathway in regulating the actin cytoskeleton and cell migration. Exp. Cell Res., 2004, 296, 183.
105. Sandsmark, D.K.; Zhang, H.; Hegedus, B.; Pelletier, C.L.; Weber, J.D.; Gutmann, D.H. Nucleophosmin mediates mammalian target of rapamycin-dependent actin cytoskeleton dynamics and proliferation in neurofibromin-deficient astrocytes. Cancer Res., 2007, 67, 4790.
106. Satoh, M.; Ogita, H.; Takeshita, K.; Mukai, Y.; Kwiatkowski, D.J.; Liao, J.K. Requirement of Rac1 in the development of cardiac hypertrophy. Proc. Natl. Acad. Sci. USA, 2006, 103, 7432.
107. Masri, J.; Bernath, A.; Martin, J.; Jo, O.D.; Vartanian, R.; Funk, A.; Gera, J. mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor. Cancer Res., 2007, 67, 11712.
108. Kahan, B.D. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet, 2000, 356, 194.
109. Keogh, A.; Richardson, M.; Ruygrok, P.; Spratt, P.; Galbraith, A.; O'Driscoll, G.; Macdonald, P.; Esmore, D.; Muller, D.; Faddy, S. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation, 2004, 110, 2694.
110. Panwalkar, A.; Verstovsek, S.; Giles, F.J. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer, 2004, 100, 657.
111. Hausleiter, J.; Kastrati, A.; Mehilli, J.; Vogeser, M.; Zohlnhofer, D.; Schuhlen, H.; Goos, C.; Pache, J.; Dotzer, F.; Pogatsa-Murray, G.; Dirschinger, J.; Heemann, U.; Schomig, A. Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial. Circulation, 2004, 110, 790.
112. Hausenloy, D.J.; Tsang, A.; Mocanu, M.M.; Yellon, D.M. Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am. J. Physiol. Heart Circ. Physiol., 2005, 288, H971.
113. Jonassen, A.K.; Sack, M.N.; Mjos, O.D.; Yellon, D.M. Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ. Res., 2001, 89, 1191.
114. Kis, A.; Yellon, D.M.; Baxter, G.F. Second window of protection following myocardial preconditioning: an essential role for PI3 kinase and p70S6 kinase. J. Mol. Cell. Cardiol., 2003, 35, 1063.
115. Khan, S.; Salloum, F.; Das, A.; Xi, L.; Vetrovec, G.W.; Kukreja, R.C. Rapamycin confers preconditioning-like protection against ischemia-reperfusion injury in isolated mouse heart and cardiomyocytes. J. Mol. Cell. Cardiol., 2006, 41, 256.
116. Gross, G.J. Rapamycin (Sirolimus): A two-edged sword? J. Molec. Cell. Cardiol., 2006, 41, 226.
117. Ghatta, S.; Tunstall, R.R.; Kareem, S.; Rahman, M.; O'Rourke, S.T. Sirolimus causes relaxation of human vascular smooth muscle: a novel action of sirolimus mediated via ATP-sensitive potassium channels. J. Pharmacol. Exp. Ther., 2007, 320, 1204.
118. Avila, G.; Dirksen, R.T. Rapamycin and FK506 reduce skeletal muscle voltage sensor expression and function. Cell Calcium, 2005, 38, 35.
119. Sarbassov, D.D.; Ali, S.M.; Sengupta, S.; Sheen, J.H.; Hsu, P.P.; Bagley, A.F.; Markhard, A.L.; Sabatini, D.M. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell, 2006, 22, 159.